Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06465108 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
A Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT06465108: Completed Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.
NCT06465108 is a Phase 2 study of Hypoparathyroidism that has completed, run by MBX Biosciences. The registered enrollment target is 64 participants, below the 193-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06465108, a Phase 2 study of Hypoparathyroidism, has completed, sponsored by MBX Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
Primary Outcome
Proportion of patients pooled across MBX 2109 doses meeting the composite criteria at week 12/Visit 15 * Independence from active vitamin D supplements * Oral elemental calcium doses of ≤600 mg/day * Serum albumin-adjusted calcium (AdjCa) values of 8.2 to 10.6 mg/dL
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MBX 2109
Study Locations (20)
New York
- MBX Biosciences Investigational Site - Albany
- MBX Biosciences Investigational Site - Great Neck
- MBX Biosciences Investigational Site - New York
- MBX Biosciences Investigational Site - The Bronx
Florida
- MBX Biosciences Investigational Site - Jacksonville
- MBX Biosciences Investigational Site - Jacksonville
- MBX Biosciences Investigational Site - Miami
Illinois
- MBX Biosciences Investigational Site - Chicago
- MBX Biosciences Investigational Site - Chicago
Nevada
- MBX Biosciences Investigational Site - Las Vegas
- MBX Biosciences Investigational Site - Reno
Ohio
- MBX Biosciences Investigational Site - Cleveland
- MBX Biosciences Investigational Site - Columbus
California
- MBX Biosciences Investigational Site - Sacramento
Georgia
- MBX Biosciences Investigational Site - Macon
Mississippi
- MBX Biosciences Investigational Site - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 2 |
What the finished NCT06465108 record still lists
NCT06465108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 193-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06465108 names 20 study sites across 12 states, led by New York, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06465108 about?
NCT06465108 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism". The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
What is the current status of trial NCT06465108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-08-08. Estimated completion is 2025-06-04.
What conditions does trial NCT06465108 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT06465108?
The interventions under investigation include: Placebo (OTHER), MBX 2109 (DRUG).
Who is sponsoring clinical trial NCT06465108?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06465108 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06465108's enrollment target sits among peer trials
64 6th of 10 higher than 5 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI